Valneva account plan
Specialty vaccine development and commercialization
At a glance
Valneva is a Lyon-based specialty vaccine company with three travel vaccines, FY2025 revenues of €174.7 million and a Lyme vaccine partnered with Pfizer.
Valneva SE develops, manufactures and sells prophylactic vaccines for infectious diseases. Its three proprietary travel vaccines, IXIARO/JESPECT (Japanese encephalitis), DUKORAL (cholera / LT-ETEC) and IXCHIQ (chikungunya), serve travelers and government and military personnel, with the U.S. Department of Defense as its single largest customer. In FY2025 it reported revenues of €174.7 million, an operating loss of €82.1 million and a net loss of €115.2 million, with 674 employees at year-end (around 620 at June 30, 2026). It manufactures in Livingston (Scotland) and Solna (Sweden), runs quality and R&D in Vienna, and is listed on Euronext Paris and the Nasdaq Global Select Market; Pfizer holds 5.51% of the shares.
Business units
IXIARO / JESPECT (Japanese encephalitis vaccine)
€98.4 million of FY2025 product salesAn inactivated vaccine and the only Japanese encephalitis vaccine approved in the U.S., Canada and the EU, required for U.S. military personnel deployed to risk areas. The U.S. Department of Defense accounted for 28.4% of IXIARO product sales in 2025, under a $32.8 million supply contract signed in January 2025. H1 2026 sales fell to €44.0 million on a new German distributor and the timing of DoD deliveries.
DUKORAL (oral cholera and LT-ETEC vaccine)
€31.9 million of FY2025 product salesAn oral vaccine produced in Solna, Sweden, acquired from Janssen in 2015, with sales concentrated in Canada and the Nordics. H1 2026 sales were €14.7 million against €17.4 million, as the prior year had included one-off supplies for a cholera outbreak in Mayotte, and gross margin fell to 24.7%.
IXCHIQ (chikungunya vaccine)
€8.4 million of FY2025 product sales (5.3% of revenues)The first licensed chikungunya vaccine. After serious adverse events mainly in elderly people, the FDA suspended the U.S. license in August 2025 and other regulators restricted use. Valneva is evaluating its future commercial strategy, including a potential focus on endemic markets, with Instituto Butantan producing a local version in Brazil.
Third-party products (distribution)
€19.2 million of FY2025 sales (12.1% of revenues)Distribution of other companies' vaccines through Valneva's commercial infrastructure, being wound down after the Bavarian Nordic agreements ended. H1 2026 sales were €1.0 million, expected to be less than 5% of product sales by year-end.
Other revenues (collaborations, licensing, technologies and services)
€16.8 million in FY2025Collaboration and licensing income, including €10.0 million recognized from the Pfizer Lyme collaboration in 2025, plus the EB66 cell line, the IC31 adjuvant and process and assay development services.
R&D pipeline
€85.3 million of R&D expenses in FY2025Led by the Lyme vaccine LB6V (formerly VLA15), partnered with Pfizer, which would handle filing, manufacturing and commercialization. Other programs include the S4V2 Shigella vaccine with LimmaTech, the Zika candidate VLA1601 (continued only with external funding) and pre-clinical EBV and ETEC candidates.
Strategic priorities
- Lyme vaccine filings with Pfizer
- The Phase 3 VALOR results announced in March 2026 showed more than 70% efficacy but missed the first pre-specified statistical criterion; Pfizer is engaging with regulators. Valneva is eligible for 14%-22% royalties, up to $100 million of sales milestones and $143 million of early commercialization milestones.
- Grow and protect the travel vaccines
- Maintain the trajectory of IXIARO and DUKORAL through access and awareness strategies aimed at travelers and health professionals, and generate as much cash as possible from the commercial business to fund R&D.
- Refocus IXCHIQ on endemic markets
- Valneva is evaluating a potential focus on endemic markets for IXCHIQ; Brazil's pilot vaccination campaign with Instituto Butantan targets 20% to 40% coverage of adults aged 18-59, and about 50,000 adults had been vaccinated by the H1 2026 report.
- Shigella and enteric vaccines
- Phase 2 results for the S4V2 Shigella vaccine were expected in Q3 2026, after which Valneva decides whether to take over late-stage development; it is also working on an ETEC candidate toward combination enteric vaccines.
- Stringent cost management
- The May 2026 restructuring reduces the global workforce by 10-15% and targets an operating expense cut of about 25-35% versus 2025, with most savings in R&D.
Latest results
In the first half of 2026 (six months to June 30), IXIARO sales fell to €44.0 million from €54.7 million, DUKORAL to €14.7 million from €17.4 million and IXCHIQ to €4.4 million from €7.5 million, while third-party sales dropped 91.6% to €1.0 million. The operating loss widened to €49.9 million (H1 2025: €16.8 million) and the net loss to €63.3 million (€20.8 million), after €9.7 million of IXCHIQ manufacturing cancellation fees and €3.2 million of restructuring expenses. Cash and cash equivalents rose to €121.5 million from €109.7 million at end-2025, helped by €34.3 million of net proceeds from the Q2 capital raise. In May 2026, citing adverse travel trends driven by geopolitical factors, the company adjusted its guidance to product sales of 135 to 150 million euros and total revenues of 145 to 160 million euros.
Investments and deals
- Pharmakon debt facility
- In October 2025 Valneva signed a non-dilutive facility of up to $500 million with funds managed by Pharmakon Advisors; the initial $215 million tranche repaid the previous loan, and maturity moved to Q4 2030.
- April 2026 reserved offering
- An up to €84 million offering of shares and warrants (€37 million at closing, up to €47 million more on warrant exercise), led by Frazier Life Sciences.
- Manufacturing transfer to Almeida
- IXIARO and IXCHIQ production is being transferred from the Manson site to the newer Almeida facility in Livingston, Scotland; capital expenditure fell to €2.7 million in 2025 from €17.2 million after the Scottish and Swedish investments.
- Footprint consolidation in France
- The Nantes site is closing, with French operations concentrated in Lyon; Nantes Métropole intends to acquire the Saint-Herblain site for €6.2 million, expected to close in September 2026.
Challenges and risks
- Weaker travel demand
- Management reported a reduced level of travel into geographies important for its travel vaccines, driven by geopolitical factors, which led to the May 2026 guidance cut.
- IXCHIQ safety and regulatory setbacks
- The U.S. license was suspended in August 2025 and the BLA withdrawn in January 2026; the end of the Serum Institute of India agreement means Valneva must find new partners for Asia.
- Manufacturing and quality
- Valneva received FDA Form 483 observations at Livingston and Vienna and a complete response letter on the IXIARO supplement for Almeida, and reported supply constraints for all three products in H1 2026.
- Dependence on Pfizer and financing
- Pfizer has sole discretion over Lyme regulatory submissions and commercialization, and the company has not achieved profitability, with ongoing funding needs and Pharmakon loan constraints.
What leadership says
“We need to maintain our existing travel vaccination offering, deliver on our financial projections and advance other programs in a diligent way”
“the vast majority of global vaccine revenue now sits in four to five Big Pharma companies.”
“the first pre-specified statistical criterion was not met, but the second one was met.”
“to generate as much cash with the commercial business as possible.”
Where a supplier can help
- Cost-reduction partners
- The restructuring targets an operating expense cut of about 25-35% versus 2025; suppliers that lower operating cost without adding headcount fit the cost-management priority.
- Manufacturing quality and compliance support
- Form 483 observations, a complete response letter on Almeida and failed batches make GMP quality, batch release and supply-planning help relevant to the manufacturing challenge.
- Market access in endemic countries
- The IXCHIQ refocus on endemic markets and the need for new Asian partners create demand for distribution, regulatory and local manufacturing partners.
- Travel-vaccine demand generation
- With weaker travel demand and a new German distributor, access and awareness programs aimed at travelers and health professionals support the priority of growing IXIARO and DUKORAL.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Valneva?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 20-F 2025
- Valneva SE is a Lyon-headquartered specialty vaccine company (listed on Euronext Paris and the Nasdaq Global Select Market), formed in 2013 by the merger of Austria's Intercell and France's Vivalis; it markets three proprietary travel vaccines: IXIARO/JESPECT (Japanese encephalitis), DUKORAL (cholera / LT-ETEC) and IXCHIQ (chikungunya).
- FY2025 revenues were €174.7 million (+3%), of which product sales €157.9 million (IXIARO €98.4 million, DUKORAL €31.9 million, third-party products €19.2 million, IXCHIQ €8.4 million); own-product sales grew 9% at constant exchange rates.
- Operating loss of €82.1 million and net loss of €115.2 million in 2025 (2024: operating profit €13.3 million, helped by the €90.8 million net gain on the sale of a Priority Review Voucher); cash of €109.7 million at year-end.
- The key value driver is the Lyme disease vaccine candidate VLA15, partnered with Pfizer (Phase 3 VALOR, 9,437 participants); Valneva is eligible for tiered royalties of 14% to 22%, up to $100 million in sales milestones and $143 million of early commercialization milestones.
- IXCHIQ suffered serious adverse events, mainly in elderly people: the FDA suspended the U.S. license in August 2025 and Valneva voluntarily withdrew the BLA and IND in January 2026; EU, UK, Brazil and Canada labels were restricted.
- The U.S. Department of Defense is a major IXIARO buyer (28.4% of IXIARO product sales in 2025; a $32.8 million supply contract signed in January 2025); third-party distribution is being wound down.
- Pipeline beyond Lyme: Shigella vaccine S4V2 (Phase 2, with LimmaTech), Zika VLA1601 (Phase 1, continued only with external funding), pre-clinical EBV, yellow fever and ETEC programs; R&D spend rose to €85.3 million.
- Refinanced with a non-dilutive Pharmakon facility of up to $500 million (initial $215 million tranche, maturity extended to Q4 2030); 674 employees at end-2025; Nantes site closing with French operations consolidated in Lyon.
- Half-Year Financial Report 2026
- H1 2026 total revenues fell to €65.8 million (H1 2025: €97.6 million) and product sales to €64.0 million (€91.0 million), due to the planned end of most third-party sales, the phasing of IXIARO shipments to the U.S. DoD, a distributor change in Germany and non-recurring outbreak-related sales in H1 2025.
- By product: IXIARO/JESPECT €44.0 million (from €54.7 million), DUKORAL €14.7 million (€17.4 million), IXCHIQ €4.4 million (€7.5 million), third-party products €1.0 million (down 91.6%).
- Operating loss widened to €49.9 million (€16.8 million) and net loss to €63.3 million (€20.8 million); adjusted EBITDA loss €40.1 million; about 50% of the operating loss came from IXCHIQ.
- IXCHIQ gross margin was negative after €9.7 million of external manufacturing cancellation fees and a €4.5 million inventory impairment, reflecting a shift of chikungunya commercial focus to endemic territories.
- Lyme candidate LB6V (formerly VLA15, with Pfizer): Phase 3 VALOR showed more than 70% efficacy but missed the first pre-specified statistical criterion; regulatory decisions are expected within twelve months and Pfizer is to submit marketing applications in H2 2026.
- Cash rose to €121.5 million at June 30, 2026 after an up to €84 million reserved offering (€37 million at closing) led by Frazier Life Sciences.
- A new restructuring program cuts the global workforce by 10-15% (about 620 employees at June 30, 2026); Nantes Métropole intends to buy the Saint-Herblain site for €6.2 million; R&D is centralized in Vienna.
- Gerd Zettlmeissl became Chair of the Board in June 2026; FDA Form 483 observations at Livingston and Vienna and a complete response letter on IXIARO production at Almeida.
- Thomas Lingelbach (Valneva): "2026 sera une année charnière pour Valneva" (EasyBourse interview)
- CEO Thomas Lingelbach called 2026 a pivotal year ("une année charnière", translated) for Valneva, with the Phase 3 VALOR readout of the Lyme disease vaccine candidate as the absolute clinical priority.
- If results were positive, partner Pfizer planned to file with the FDA and EMA by year-end; the vaccine could transform Valneva through milestone payments and future royalties.
- Commercial goals: grow IXIARO and DUKORAL and develop IXCHIQ in existing and future markets, with a focus on low- and middle-income countries affected by recurring outbreaks.
- Cost discipline continues: cash consumption fell 63% over the first nine months of 2025, per the CEO.
- The commercial portfolio acts as a safety net that distinguishes Valneva from development-only biotechs.
- Partnerships are central: Pfizer (Lyme, where Valneva lacks the commercial capabilities alone), CEPI and Instituto Butantan (chikungunya), LimmaTech (Shigella), CSL Seqirus (distribution in Germany since June 2025).
- "technology agnostic" pipeline approach (English in the original): the disease dictates the platform; mRNA, viral vectors or new adjuvants are not ruled out.
- Two production sites (Scotland for viral vaccines, Sweden for bacterial vaccines); production moved from Manson to the new Almeida facility.
- Leading Forward: Key Takeaways from 2025 and Priorities for 2026
- In a Q&A-style piece on Valneva's website (January 21, 2026), CEO Thomas Lingelbach reviewed 2025 and set out priorities for what he called a pivotal 2026.
- 2025 required reprioritizing investments and consolidating the corporate footprint to improve cash flows; refinancing the debt ahead of Lyme data was "a major achievement".
- The Lyme candidate VLA15 (pivotal Phase 3 data expected in H1 2026) "will have a transformational impact on the organization"; he wants to "rapidly increase scale" around such moments.
- Fundamentals for 2026: maintain the travel vaccine offering, deliver financial projections, ensure compliance and optimal supply.
- Partnerships with Pfizer, CEPI and Instituto Butantan are cornerstones; the Pfizer collaboration "sets a benchmark for the industry".
- Industry consolidation leaves most global vaccine revenue with four to five Big Pharma companies; Valneva's niche is specialized targets outside big pharma's scale expectations and access through local partnerships.
- Leadership theme for 2026: resilience and a positive attitude to change.
- Q1 2026 Earnings Conference Call Transcript
- Q1 2026 call (May 13, 2026) with CEO Thomas Lingelbach and CFO Peter Buehler, dominated by the Lyme Phase 3 readout: efficacy above 70%, the first pre-specified statistical criterion missed, the second met; Pfizer is planning regulatory submissions.
- Q1 product sales €30.5 million (vs €48.6 million), total revenues €30.9 million; IXIARO €20.2 million (DoD phasing), DUKORAL €8.6 million, IXCHIQ €1.6 million; net loss €32.1 million; cash €105 million before the April offering.
- 2026 guidance cut to product sales of €135-150 million and total revenues of €145-160 million, citing reduced travel to key geographies amid geopolitical factors.
- Restructuring: global workforce reduction of 10-15% (much of it in Austria) and a 25-35% cut in operating expenses versus 2025, mostly in R&D.
- Chikungunya: Brazil pilot campaign has vaccinated more than 30,000 people, aiming for much more than 100,000; Butantan's locally produced vaccine licensed in Brazil.
- Shigella Phase 2 readouts expected over the summer; long-term vision of enteric combination vaccines (Shigella, ETEC, cholera) for LMICs and travelers.
- Post-Lyme strategy: build R&D scale organically and inorganically, beyond vector-borne diseases; FDA issues at the Almeida site do not affect U.S. IXIARO supply from Manson, per the CEO.
Questions about Valneva
What does Valneva do?
Valneva is a specialty vaccine company that develops, manufactures and sells prophylactic vaccines for infectious diseases. It markets three travel vaccines, IXIARO/JESPECT, DUKORAL and IXCHIQ, and is developing a Lyme disease vaccine with Pfizer.
What was Valneva's revenue in 2025?
FY2025 revenues were €174.7 million, of which €157.9 million of product sales, with an operating loss of €82.1 million and a net loss of €115.2 million.
How many employees does Valneva have?
Valneva had 674 employees at December 31, 2025 and around 620 at June 30, 2026, and its May 2026 restructuring reduces the global workforce by 10-15%.
Who leads Valneva?
Thomas Lingelbach has been President & CEO since 2013 and was reappointed for three years in June 2026; Peter Bühler is CFO and Gerd Zettlmeissl chairs the Board.
What is Valneva's strategy?
Valneva aims to secure filings for its Lyme vaccine with Pfizer, grow its travel vaccines, advance its Shigella and enteric programs, and keep stringent cost management.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)